Development Scientist III, Viral Vector Analytical Development
Alexion Pharmaceuticals, Inc.Highlight
Summary
About the Role
About You
- BS in Molecular Biology, Biochemistry, or related field with 10+ years of relevant experience, a MS with 8+ years of experience, or PhD with 4+ years of experience.
- Strong hands-on experience in the development, qualification/validation, and transfer of biochemical and biophysical methods for assessing viral vectors.
- Prior experience with mass spectrometry, surface plasmon resonance, mass photometry, or analytical ultracentrifugation.
- Demonstrated ability to utilize standard office and data analysis software.
Benefits
- Annual base pay ranging from $138k to $208k.
- Short-term incentive bonus opportunity.
- Equity-based long-term incentive program eligibility.
- 401(k) retirement plan.
- Paid vacation and holidays.
- Health benefits including medical, dental, and vision coverage.
Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies, and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by understanding their experiences, Alexion is better able to serve their unique needs. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally. GL/NP/0116 GL/NP/0095 Community Guidelines: https://bit.ly/39x9gqy